

References

1. Sidana S, Tandon N, Dispenzieri A, et al. Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. *Leukemia*. 2019 Mar;33(3):730-738. doi: 10.1038/s41375-018-0271-1. Epub 2018 Oct 15. PMID: 30323358.
2. Kumar S, Callander NS, Adekola K, et al. NCCN Clinical Practice Guidelines in Oncology, Multiple Myeloma, Version 2.2024. *J Natl Compr Canc Netw*. 2023;21(12):1281–1301. doi: <https://doi.org/10.6004/jnccn.2023.0061>
3. Rajkumar, SV, Kumar, S. Multiple myeloma current treatment algorithms. *Blood Cancer J*. 2020 Sep 28;10(9):94. <https://doi.org/10.1038/s41408-020-00359-2>
4. Bahlis NJ, Siegel DS, Schiller GJ, et al. Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial. *Leuk Lymphoma*. 2022 Jun;63(6):1407-1417. doi: 10.1080/10428194.2022.2030477. Epub 2022 Feb 8. PMID: 35133221.
5. Richardson PG, Oriol A, Beksac M, et al. OPTIMISMM trial investigators. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. PMID: 31097405.
6. Dimopoulos M, Weisel K, Moreau P, et al. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. *Leukemia*. 2021 Jun;35(6):1722-1731. doi: 10.1038/s41375-020-01021-3. Epub 2020 Sep 7. PMID: 32895455; PMCID: PMC8179841.
7. Pierceall WE, Amatangelo MD, Bahlis NJ, et al. Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma. *Clin Cancer Res*. 2020 Nov 15;26(22):5895-5902. doi: 10.1158/1078-0432.CCR-20-1781. Epub 2020 Sep 14. PMID: 32928795.
8. Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. *Lancet*. 2020 Jul 18;396(10245):186-197. doi: 10.1016/S0140-6736(20)30734-0. Erratum in: *Lancet*. 2020 Aug 15;396(10249):466. PMID: 32682484.
9. Moreau P, Dimopoulos MA, Mikhael J, et al. IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. *Lancet*. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4. PMID: 34097854.

The Cutting Edge of Multiple Myeloma: The Evolving Role of CD38-directed Strategies
The MM Journey Continues: CD38-targeting Agents in the Relapsed/Refractory Setting

10. Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. *Blood*. 2017 Aug 24;130(8):974-981. doi: 10.1182/blood-2017-05-785246. Epub 2017 Jun 21. PMID: 28637662; PMCID: PMC5570682.
11. Attal M, Richardson PG, Rajkumar SV, et al. ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. *Lancet*. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14. Erratum in: *Lancet*. 2019 Dec 7;394(10214):2072. PMID: 31735560.
12. Dimopoulos MA, Terpos E, Boccadoro M, et al. APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. *Lancet Oncol*. 2021 Jun;22(6):801-812. doi: 10.1016/S1470-2045(21)00128-5. PMID: 34087126.
13. Berenson JR, Cartmell A, Bessudo A, et al. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. *Blood*. 2016 Jun 30;127(26):3360-3368. doi: 10.1182/blood-2015-11-683854. Epub 2016 May 12. PMID: 27207788; PMCID: PMC4929927.
14. Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. *Blood*. 2017 Nov 30;130(22):2401-2409. doi: 10.1182/blood-2017-06-788786. Epub 2017 Oct 10. PMID: 29018077.
15. Gupta VA, Barwick BG, Matulis SM, et al. Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. *Blood*. 2021 Jul 1;137(26):3604-3615. doi: 10.1182/blood.2020007899. PMID: 33649772; PMCID: PMC8462405.
16. Touzeau C, Dousset C, Le Gouill S, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. *Leukemia*. 2014 Jan;28(1):210-212. doi: 10.1038/leu.2013.216. Epub 2013 Jul 17. PMID: 23860449; PMCID: PMC3887407.
17. Mateos MV, Beksac M, Dimopoulos MA, et al: Results from the randomized, open-label phase 3 CANOVA study of venetoclax-dexamethasone versus pomalidomide-dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma. International Myeloma Society 2023 Annual Meeting. Abstract OA-52. Presented September 29, 2023.
18. Bahlis NJ, Baz R, Harrison SJ, et al. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). *J Clin Oncol*. 2021 Nov 10;39(32):3602-3612. doi: 10.1200/JCO.21.00443. Epub 2021 Aug 13. PMID: 34388020; PMCID: PMC8577687.
19. White D, Chen C, Baljevic M, et al. Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM). *J Clin Oncol*. 2021;39(15_suppl):8018. https://doi.org/10.1200/JCO.2021.39.15_suppl.8018.

The Cutting Edge of Multiple Myeloma: The Evolving Role of CD38-directed Strategies
The MM Journey Continues: CD38-targeting Agents in the Relapsed/Refractory Setting

20. Dwivedi S, Rendón-Huerta EP, Ortiz-Navarrete V, Montañño LF. CD38 and Regulation of the Immune Response Cells in Cancer. *J Oncol*. 2021 Feb 27;2021:6630295. doi: 10.1155/2021/6630295. PMID: 33727923; PMCID: PMC7936891.
21. Sebag M, Bahlis N, Venner C, et al. CMRG 004: A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma. *Blood* 2019; 134 (Supplement_1): 3121. doi: <https://doi.org/10.1182/blood-2019-124457>
22. Guedes AG, Dileepan M, Jude JA, et al. Role of CD38/cADPR signaling in obstructive pulmonary diseases. *Curr Opin Pharmacol*. 2020 Apr;51:29-33. doi: 10.1016/j.coph.2020.04.007. Epub 2020 May 29. PMID: 32480246; PMCID: PMC7529733.
23. Chari A, Mark TM, Krishnan A, et al. Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma. *Blood*. 2016;128(22):2142. doi: <https://doi.org/10.1182/blood.V128.22.2142.2142>
24. San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. *N Engl J Med*. 2023;389:335-347 DOI: 10.1056/NEJMoa2303379

Provided by MediCom Worldwide, Inc.

This activity is supported by an educational grant from sanofi-aventis US LLC